Obsidian Therapeutics to Merge with Galera and Raise $350 Million to Advance TIL Cell Therapy
Galera and Obsidian merge to form OBX, advancing TIL cancer therapy for melanoma & lung cancer, backed by $350M funding.
Galera and Obsidian merge to form OBX, advancing TIL cancer therapy for melanoma & lung cancer, backed by $350M funding.
Avanos Medical is being bought by AIP for $1.27B in cash. Shareholders get $25 per share, a big premium. Company goes private in 2026.
FDA approved FILSPARI for FSGS kidney disease, showing it lowers protein in urine and slows damage. It offers a new treatment option for patients with few choices.
Novo Nordisk teams with OpenAI to use AI for faster drug discovery, production and sales, aiming to catch rivals like Eli Lilly.
Sana + Mayo Clinic are testing SC451, a cell therapy that may treat type 1 diabetes without daily insulin shots or immune drugs.
New drug daraxonrasib from Revolution Medicines doubled survival in pancreatic cancer (13.2 vs 6.7 months) and cut death risk by 60% in Phase 3.